|Slideshows|November 23, 2020

Top 10 Reasons to be Grateful During the COVID-19 Pandemic

As the countdown to the new year slowly dwindles down, remember the things you can be thankful for in 2020, as hard as it may have been.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe Now!

Related Content

What Long COVID Can Teach Psychiatry—and Its Critics

ByRonald W. Pies, MD

July 8th 2025

The Week in Review: March 24-28

ByLeah Kuntz

March 28th 2025

Post-Acute Sequelae of COVID-19 Infection Presenting With Neuropsychiatric Symptoms: Diagnosis and Management

ByMeghan Reddy, MD,Kalyn Reddy, MD, MPH,Hanadi Ajam Oughli, MD,Sarah A. Nguyen, MD,Helen Lavretsky, MD, MS

March 28th 2025

What Does the 5th Year Anniversary of COVID-19 Mean to You?

ByH. Steven Moffic, MD

March 19th 2025

How Not to Mourn COVID-19

ByH. Steven Moffic, MD

March 17th 2025

Latest CME

Case-based Simulation

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Nicholas Doher, DO; Babak Tousi, MD

In-Person + Virtual Event

Real Psychiatry 2026

January 23-24, 2026

Video

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Michael Asbach, DMSc, PA-C; Erin Crown, MHS, PA-C, Psych-CAQ

Video

Optimizing Care for Patients With Tardive Dyskinesia

Amber Hoberg, MSN, APRN, PMHNP-BC; Erin Crown, PA-C, Psych-CAQ

Video

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Jonathan Meyer, MD; Jacob Hanaie, PharmD, APh, BCPP; Sanjai Rao, MD, DFAPA

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Top 10 Reasons to be Grateful During the COVID-19 Pandemic

Newsletter

Related Content

What Long COVID Can Teach Psychiatry—and Its Critics

The Week in Review: March 24-28

Post-Acute Sequelae of COVID-19 Infection Presenting With Neuropsychiatric Symptoms: Diagnosis and Management

What Does the 5th Year Anniversary of COVID-19 Mean to You?

How Not to Mourn COVID-19

Latest CME

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Real Psychiatry 2026

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Optimizing Care for Patients With Tardive Dyskinesia

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

The Epstein Files, the Abuse of Women, and Psychiatry

Interrelation of Hormones and Adult ADHD

FDA Clears Investigational New Drug Application for TNX-102 SL for Treatment of Major Depressive Disorder

New Drug Application Submitted for Centanafidine for Treatment of ADHD

Lecanemab or Lithium? Compare Benefits, Risks, and Dose